Myelosuppression after autologous hematopoietic stem cell transplantation
Conditions
Interventions
intervention group:G-CSF combined with leucogen
Control group:G-CSF
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-70 years old, gender unlimited; 2.Autologous hematopoietic stem cell transplantation for patients with blood diseases; 3.Overall Physical Status Score (ECOG) 0-2; 4.Estimated survival time > 3 months; 5.Study participants volunteered to participate in the study, had a good understanding of the treatment and follow-up received in the study program, were able to understand the study process, and voluntarily signed informed consent;
Exclusion criteria
Exclusion criteria: 1.There are other major complications of heart, liver and kidney; 2.Patients with myelodysplastic symptoms; 3.Hyperelevated blood cell drugs were used within 2 weeks before enrollment; 4.During the pretreatment period, radiotherapy was accompanied by chemotherapy; 5.Patients allergic to G-CSF or leucogen; 6.Hiv-positive patients; 7.Patients with poor compliance or mental abnormalities; 8.Patients with potentially life-threatening or severe organ dysfunction were deemed unfit to participate in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutrophil engraftment time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet engraftment time;Febrile Neutropenia (FN) incidence rate;total platelet transfusion volume; | — |
Countries
China
Contacts
Public ContactDongfeng Zeng
Army Medical Center of PLA
Outcome results
None listed